Search

Your search keyword '"Concin, Nicole"' showing total 316 results

Search Constraints

Start Over You searched for: Author "Concin, Nicole" Remove constraint Author: "Concin, Nicole" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
316 results on '"Concin, Nicole"'

Search Results

1. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

3. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

4. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

5. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer—a study of the OVCAD consortium

7. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

8. Lymph node staging in grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?

10. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres

11. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

12. Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer

13. The Predictive Value of the Fibrinogen–Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer.

14. Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?

15. Gene expression markers in peripheral blood and outcome in patients with platinum‐resistant ovarian cancer: A study of the European GANNET53 consortium.

16. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)‐induced phenotypes for platinum sensitivity and long‐term survival in ovarian cancer—A study from the OVCAD consortium.

17. Uterine serous carcinoma

18. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

19. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

23. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

25. Response to: Correspondence on 'ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors' by Thomassin-Nagarra et al

26. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

27. The genetic landscape of 87 ovarian germ cell tumors

30. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

31. Response: FIGO staging of endometrial cancer 2023.

32. Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis.

39. Gestational choriocarcinoma.

40. FIGO staging of endometrial cancer: 2023.

44. Prognostic factors in patients with uterine sarcoma: the SARCUT study.

45. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients.

48. Endometrial carcinosarcoma.

49. Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.

Catalog

Books, media, physical & digital resources